- Pfizer Inc shares traded 3.27 % higher to $28.15 on Wednesday, moving in sympathy with mRNA cancer vaccine-related companies.
- The rally follows Merck and Moderna announcing positive Phase 3 trial results for their combination mRNA cancer treatment and Keytruda in melanoma patients.
- Investors extended optimism to Pfizer due to its established partnership with BioNTech and its status as a market mRNA proxy.
- Arbutus Biopharma reported a Q2 FY26 net loss of $5.1 million and a 90.56% revenue drop to $1.01 million.
- The company reduced R&D expenses by 47.27% to $2.9 million and held $92.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
- Arbutus plans to repurchase up to about $230 million of shares starting in Q3 and has filed international patent enforcement suits against Pfizer and BioNTech.